Pherecydes Pharma Announces Its 2022 Annual Financial Results and Specifies Its Development Plan For 2023

Proposed strategic combination with Erytech Pharma intending to create a global leader in phage therapies: Acceleration in the development of phage therapy in antimicrobial resistance

Related Keywords

Mauritius ,United States ,Sweden ,Paris ,France General ,France ,French ,Ile De France ,Swedish ,American ,Dusan Oresansky Nicolas Fossiez ,Pherecydes Pharma ,Didier Hoch ,Erytech Pharma ,Arthur Rouill ,Swedish Medical Products Agency ,Research Tax Credit ,Ethics Committee Comit ,Va Research Development ,Early Access Program Approval ,Shareholder Meetings ,Tax Credit ,Ethics Committee ,French National Agency ,Data Safety Monitoring Board ,Shareholder Meeting ,Combined Shareholder Meeting ,Chief Executive Officer ,Access Program Approval ,Medical Advisory ,Medical Advisory Board ,Research Development ,North American ,Extraordinary General Meetings ,Oresansky Nicolas Fossiez ,Pherecydes ,Dharma ,Nnounces ,022 ,Nnual ,Financial ,Results ,Specifies ,Development ,Plan ,023 ,